Compare WYY & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WYY | ACET |
|---|---|---|
| Founded | 1991 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.2M | 69.6M |
| IPO Year | 2005 | 2017 |
| Metric | WYY | ACET |
|---|---|---|
| Price | $5.05 | $7.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $8.67 | ★ $56.00 |
| AVG Volume (30 Days) | 33.1K | ★ 112.4K |
| Earning Date | 01-01-0001 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.35 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,571,749.00 | N/A |
| Revenue This Year | $5.20 | N/A |
| Revenue Next Year | $15.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 34.47 | N/A |
| 52 Week Low | $2.19 | $0.45 |
| 52 Week High | $7.55 | $9.05 |
| Indicator | WYY | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 43.92 |
| Support Level | $3.96 | $6.54 |
| Resistance Level | $5.90 | $8.34 |
| Average True Range (ATR) | 0.29 | 0.44 |
| MACD | 0.12 | -0.07 |
| Stochastic Oscillator | 73.54 | 10.23 |
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.